lepirudin

DRUG4 trials

Sponsors

Dartmouth-Hitchcock Medical Center, National Institutes of Health Clinical Center (CC), Heinrich-Heine University, Duesseldorf, GlaxoSmithKline

Conditions

Acute HIT II (Heparin-induced Thrombocytopenia Type II)Heparin Induced Thrombocytopenia (HIT)Lung CancerThrombosis

Phase 1

Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer

TerminatedNCT00003726

Dartmouth-Hitchcock Medical CenterLung Cancer

Start: 1998-11-30End: 2001-07-31Updated: 2016-08-08

Phase 2

Heparin Versus Lepirudin Flushes in Preventing Blockage of Venous Access Devices

CompletedNCT00039767

National Institutes of Health Clinical Center (CC)Thrombosis

Start: 2002-05-31End: 2006-04-30Target: 340Updated: 2008-03-04

Phase 4

Argatroban Versus Lepirudin in Critically Ill Patients

TerminatedNCT00798525

Heinrich-Heine University, DuesseldorfHeparin Induced Thrombocytopenia (HIT)

Start: 2009-01-31End: 2012-03-31Updated: 2012-06-21

Unknown Phase

Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II

CompletedNCT01304238

GlaxoSmithKlineAcute HIT II (Heparin-induced Thrombocytopenia Type II)

Start: 2009-02-28End: 2010-01-31Updated: 2017-07-06

Related Papers

Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.

2018-02-0926 citations

Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.

2017-11-0141 citations

Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial

Critical Care2014-10-2427 citations